


PHARMACEUTICAL 2020

ESPERION

Esperion Therapeutics Inc. Rank 182 of 362





PHARMACEUTICAL 2020

ESPERION

Esperion Therapeutics Inc. Rank 182 of 362

The relative strengths and weaknesses of Esperion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Esperion Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 207% points. The greatest weakness of Esperion Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is -182%, being 121% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	211,714
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	66,080
Liabilities, Non-Current	1,109
Other Assets	1,588
Other Compr. Net Income	342
Other Expenses	8,120
Other Liabilities	127,308
Other Net Income	4,056
Property and Equipment	1,145
Research and Development	175,611
Revenues	148,364
Selling, General and Administrative Expense	65,854

Output Variable	Value in 1000 USD
Assets	214,447
Liabilities	194,497
Expenses	249,585
Stockholders Equity	19,950
Net Income	-97,165
Comprehensive Net Income	-96,994
Economic Capital Ratio	-182%